Literature DB >> 12946442

The suppressive effect of triptolide on experimental autoimmune uveoretinitis by down-regulating Th1-type response.

Yadi Wu1, Yanping Wang, Cuiping Zhong, Yuanchao Li, Xiaoyu Li, Bing Sun.   

Abstract

We investigated the suppressive effect of triptolide (TRD), a purified component from a traditional Chinese herb, Tripterygium wilfordii Hook F. (TWHf), on uveitogenic peptide (K2)-induced experimental autoimmune uveoretinitis (EAU). K2-peptide immunized B10.A mice were divided into four groups. One group was EAU control which was treated with PBS. The other two groups were treated with TRD with different time courses (from day 0 to day 28 and from day 14 to day 28). The last group was treated with Cyclosporin A (CsA) as a positive control of the treatment. TRD was administered at dose of 0.1 mg/kg/day (i.p.). CsA was administered at dose of 20 mg/kg/day (i.p.) from day 0 to day 28 during whole period of EAU induction. The data showed that the EAU was suppressed in the whole period of TRD-treated mice, but was not in TRD-treated mice from day 14 to day 28 following immunization. The inhibition of EAU induced by TRD treatment was comparable to CsA-treated mice. The K2-specific lymphocyte proliferation and mRNA expressions of Th1-type cytokines (IL-12p40, IFN-gamma and TNF-alpha) in draining lymph node and inflamed eyes were reduced in TRD-treated mice. The K2-specific IFN-gamma production in the draining lymph node cells (LNC) of TRD-treated mice (whole period) was significantly inhibited. This effect was not related to an apoptotic effect of TRD on CD4+ T cells. Our results suggested that TRD suppressed the induction of EAU by down-regulating Th1-type response in B10.A mice. This preventive effect on EAU induction may be related to the inhibition of TRD on T cell priming and activation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12946442     DOI: 10.1016/S1567-5769(03)00144-9

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  9 in total

Review 1.  Triptolide in the treatment of psoriasis and other immune-mediated inflammatory diseases.

Authors:  Rui Han; Martin Rostami-Yazdi; Sascha Gerdes; Ulrich Mrowietz
Journal:  Br J Clin Pharmacol       Date:  2012-09       Impact factor: 4.335

2.  Triptolide, a constituent of immunosuppressive Chinese herbal medicine, is a potent suppressor of dendritic-cell maturation and trafficking.

Authors:  Xin Chen; Takaya Murakami; Joost J Oppenheim; O M Zack Howard
Journal:  Blood       Date:  2005-06-14       Impact factor: 22.113

3.  Inhibitory effects of triptolide on titanium particle-induced osteolysis and receptor activator of nuclear factor-κB ligand-mediated osteoclast differentiation.

Authors:  Ju Ang Kim; Hye Jung Ihn; Ju-Young Park; Jiwon Lim; Jung Min Hong; Sang Hyun Kim; Shin-Yoon Kim; Hong-In Shin; Eui Kyun Park
Journal:  Int Orthop       Date:  2014-11-23       Impact factor: 3.075

4.  Triptolide induces anti-inflammatory cellular responses.

Authors:  Ranyia Matta; Xianxi Wang; Hui Ge; William Ray; Leif D Nelin; Yusen Liu
Journal:  Am J Transl Res       Date:  2009-03-05       Impact factor: 4.060

5.  Triptolide-mediated inhibition of interferon signaling enhances vesicular stomatitis virus-based oncolysis.

Authors:  Fethia Ben Yebdri; Julien Van Grevenynghe; Vera A Tang; Marie-Line Goulet; Jian Hui Wu; David F Stojdl; John Hiscott; Rongtuan Lin
Journal:  Mol Ther       Date:  2013-08-28       Impact factor: 11.454

6.  Triptolide ameliorates colonic fibrosis in an experimental rat model.

Authors:  Qingsong Tao; Baochai Wang; Yu Zheng; Guanwei Li; Jianan Ren
Journal:  Mol Med Rep       Date:  2015-04-01       Impact factor: 2.952

7.  Triptolide inhibits CD4+ memory T cell-mediated acute rejection and prolongs cardiac allograft survival in mice.

Authors:  Shuiwei Qiu; Dingliang Lv
Journal:  Exp Ther Med       Date:  2017-08-02       Impact factor: 2.447

8.  Efficacy and safety of tripterygium glycosides for active moderate to severe Graves' ophthalmopathy: a randomised, observer-masked, single-centre trial.

Authors:  Xiaozhen Ye; Heng Zhao; Jun Liu; Bin Lu; Jiaqing Shao; Jian Wang
Journal:  Eur J Endocrinol       Date:  2021-02       Impact factor: 6.664

9.  Identification of an epitope of SARS-coronavirus nucleocapsid protein.

Authors:  Ying Lin; Xu Shen; Rui Fu Yang; Yi Xue Li; Yong Yong Ji; You Yu He; Mu De Shi; Wei Lu; Tie Liu Shi; Jin Wang; Hong Xia Wang; Hua Liang Jiang; Jian Hua Shen; You Hua Xie; Yuan Wang; Gang Pei; Bei Fen Shen; Jia Rui Wu; Bing Sun
Journal:  Cell Res       Date:  2003-06       Impact factor: 25.617

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.